In this article, we break down the Top 5 Biotech Stocks That Could Climb as Much as 100%. For investors looking for the complete list, you can explore our full report on the Top 10 Biotech Stocks That Could Climb as Much as 100%.
5. Tango Therapeutics Inc. (NASDAQ:TNGX)
Tango Therapeutics, Inc. (NASDAQ: TNGX) is the most speculative name from the uploaded list, but it is also the kind of biotech stock that aggressive investors often watch because the upside depends on clinical catalysts. Tango is a clinical-stage oncology company focused on precision cancer medicines, with its leading story built around vopimetostat, a PRMT5 inhibitor. Based on latest market data, Tango traded at $20.56, with a market capitalization of about $2.95 billion. The uploaded screen showed a huge 68.53% 12-week price change, but also no forward P/E, projected EPS decline, and no projected sales growth, which tells investors exactly what this is: a data-driven biotech bet, not an earnings-driven company yet.
The latest available Q1 2026 update showed that Tango ended March 31, 2026 with about $380 million in cash, and the company said its runway extends into 2028. That is important because clinical-stage biotech companies live and die by cash runway. Tango also indicated that first clinical data from its PRMT5/RAS(ON) combination trial are expected in 2026, making the stock heavily dependent on upcoming oncology data. Its focus on pancreatic cancer and MTAP-deleted tumors gives the company exposure to large areas of unmet medical need, but also places it in a brutally competitive and scientifically difficult field.
The bullish case is that if vopimetostat shows convincing safety and efficacy, Tango could move closer to pivotal development and attract more institutional attention. The bearish case is that negative or even merely underwhelming data could hit the stock hard, especially after a major 12-week run. Investors also need to remember that Tango has no meaningful product revenue yet, so valuation depends on clinical confidence, partner confidence, and the market’s appetite for oncology risk. For risk-tolerant biotech investors, TNGX may be worth watching, but this is not a “safe” biotech stock. It is a catalyst stock, and the next major move will likely come from data, not from quarterly earnings.
Click next to see the following stock...
